Iovance Biotherapeutics's total assets for Q4 2024 were $910.43M, a decrease of -8.14% from the previous quarter. IOVA total liabilities were $200.02M for the fiscal quarter, a -8.10% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.